MA32763B1 - Composition vétérinaire antiprolactinique destinés aux ruminants - Google Patents

Composition vétérinaire antiprolactinique destinés aux ruminants

Info

Publication number
MA32763B1
MA32763B1 MA33803A MA33803A MA32763B1 MA 32763 B1 MA32763 B1 MA 32763B1 MA 33803 A MA33803 A MA 33803A MA 33803 A MA33803 A MA 33803A MA 32763 B1 MA32763 B1 MA 32763B1
Authority
MA
Morocco
Prior art keywords
ruminants
veterinary composition
prolactin
antiprolactinic
antiprolactinic veterinary
Prior art date
Application number
MA33803A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Anouck Lagarde
Stephane Floch
Thierry Bertaim
Original Assignee
Ceva Sante Animale Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40527505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32763(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ceva Sante Animale Sa filed Critical Ceva Sante Animale Sa
Publication of MA32763B1 publication Critical patent/MA32763B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA33803A 2008-10-07 2011-05-02 Composition vétérinaire antiprolactinique destinés aux ruminants MA32763B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0805544A FR2936710B1 (fr) 2008-10-07 2008-10-07 Composition veterinaire antiprolactinique destinee aux ruminants
PCT/EP2009/063004 WO2010040765A1 (fr) 2008-10-07 2009-10-07 Composition veterinaire antiprolactinique destinee aux ruminants

Publications (1)

Publication Number Publication Date
MA32763B1 true MA32763B1 (fr) 2011-11-01

Family

ID=40527505

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33803A MA32763B1 (fr) 2008-10-07 2011-05-02 Composition vétérinaire antiprolactinique destinés aux ruminants

Country Status (24)

Country Link
US (2) US9730923B2 (https=)
EP (1) EP2349272B1 (https=)
JP (1) JP5955561B2 (https=)
KR (2) KR101892559B1 (https=)
CN (1) CN102215843B (https=)
AU (1) AU2009301134B2 (https=)
BR (1) BRPI0914064A2 (https=)
CA (1) CA2738875C (https=)
DK (1) DK2349272T3 (https=)
ES (1) ES2719844T3 (https=)
FR (1) FR2936710B1 (https=)
HU (2) HUE043239T2 (https=)
IL (1) IL212125B (https=)
MA (1) MA32763B1 (https=)
MX (1) MX2011003743A (https=)
NO (1) NO2019028I1 (https=)
NZ (1) NZ592288A (https=)
PL (1) PL2349272T3 (https=)
PT (1) PT2349272T (https=)
RU (1) RU2528892C2 (https=)
SI (1) SI2349272T1 (https=)
UA (1) UA103779C2 (https=)
WO (1) WO2010040765A1 (https=)
ZA (1) ZA201103273B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2971423B1 (fr) 2011-02-15 2014-01-10 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
EP2995297A1 (fr) * 2014-09-09 2016-03-16 Ceva Sante Animale Compositions parentérales et leurs utilisations
US20200071408A1 (en) 2016-11-29 2020-03-05 National Center Of Neurology And Psychiatry Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
EP4064854A1 (en) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors in the drying-off of non-human mammals
UY39022A (es) * 2020-01-27 2021-07-30 Ceva Sante Animale Composición veterinaria de anti-prolactina para rumiantes utilizada mediante administración intramamaria
AR122366A1 (es) * 2020-01-27 2022-09-07 Ceva Sante Animale Composición veterinaria para rumiantes lecheros para el tratamiento de la fiebre de la leche

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839171A (en) * 1984-11-30 1989-06-13 Techmix, Inc. Composition for treating impaired lactation
US4939259A (en) * 1989-07-24 1990-07-03 Eli Lilly And Company 2-oxo-pyrido[2,3-g]quinoline derivatives
WO2000054776A1 (en) * 1999-03-17 2000-09-21 Eugen Eigenmann Use of prolactin inhibitors for the treatment of fertility problems in animal species
GB0108485D0 (en) * 2001-04-04 2001-05-23 Pfizer Ltd Combination therapy
NZ515178A (en) * 2001-11-23 2004-09-24 Agres Ltd Modulating prolactin receptors to affect a physiological response
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
GB0314469D0 (en) 2003-06-20 2003-07-23 Phico Therapeutics Ltd Antimicrobial compositions and uses thereof
CN1762495B (zh) * 2004-09-21 2011-04-06 山东绿叶制药有限公司 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺
KR20070059161A (ko) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
ITTO20070479A1 (it) * 2007-07-02 2009-01-03 Ceva Vetem S P A Composizione veterinaria iniettabile ad attivita' anti-prolattinica

Also Published As

Publication number Publication date
KR20170017002A (ko) 2017-02-14
CN102215843A (zh) 2011-10-12
KR20110110091A (ko) 2011-10-06
US20110245261A1 (en) 2011-10-06
PT2349272T (pt) 2019-05-13
DK2349272T3 (da) 2019-04-29
SI2349272T1 (sl) 2019-07-31
MX2011003743A (es) 2011-07-28
RU2011118366A (ru) 2012-11-20
AU2009301134B2 (en) 2013-12-05
CA2738875C (fr) 2017-11-21
EP2349272A1 (fr) 2011-08-03
EP2349272B1 (fr) 2019-01-16
ES2719844T3 (es) 2019-07-16
HK1161555A1 (en) 2012-07-27
BRPI0914064A2 (pt) 2015-11-03
HUS1900036I1 (hu) 2019-07-29
FR2936710B1 (fr) 2011-01-07
RU2528892C2 (ru) 2014-09-20
IL212125B (en) 2020-06-30
US20130203762A1 (en) 2013-08-08
ZA201103273B (en) 2012-07-25
JP5955561B2 (ja) 2016-07-20
IL212125A0 (en) 2011-06-30
NO2019028I1 (no) 2019-07-05
FR2936710A1 (fr) 2010-04-09
PL2349272T3 (pl) 2019-08-30
NZ592288A (en) 2013-03-28
HUE043239T2 (hu) 2019-08-28
AU2009301134A1 (en) 2010-04-15
CN102215843B (zh) 2014-07-30
US9744158B2 (en) 2017-08-29
KR101892559B1 (ko) 2018-08-28
WO2010040765A1 (fr) 2010-04-15
CA2738875A1 (fr) 2010-04-15
US9730923B2 (en) 2017-08-15
UA103779C2 (ru) 2013-11-25
JP2012505178A (ja) 2012-03-01

Similar Documents

Publication Publication Date Title
MA32763B1 (fr) Composition vétérinaire antiprolactinique destinés aux ruminants
DK201470535A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
WO2010148007A3 (en) Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
BRPI0507279A (pt) método e dispositivo para o tratamento do canal da teta de um animal
WO2012012498A3 (en) Use of trp channel agonists to treat infections
MX2010004281A (es) Composiciones y metodos para el tratamiento de la retinopatia diabetica.
MX368880B (es) Dexmedetomidina y medetomidina para su uso en el alivio de la aversión al ruido en un animal.
UA106199C2 (ru) Производные аминобензамида как агенты, пригодные для использования для борьбы с паразитами животных
FI3721882T3 (fi) Aineenvaihduntahäiriöiden hoito hevoseläimissä
CL2012003171A1 (es) Compuestos derivados de ciclohexilamina, con actividad dual agonista con el receptor m3 muscarinico y agonista con el receptor b2 adrenérgicos; composición farmacéutica que comprende un compuesto; combinación; farmaceutica; y su uso de un compuesto en la preparacion de medicamento de enfermedades respiratorias.
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
MX340489B (es) Combinaciones que comprenden antipsicoticos atipicos y agonistas de receptor 1 asociado a aminas traza (taar1).
UA102565C2 (ru) Фармацевтическая композиция для системного лечения инвазии паразитов, которые сосут кровь или кормятся кровью, которая как антипаразитический препарат содержит имидаклоприд
PH12018501588A1 (en) 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
TN2015000440A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
FR2971423B1 (fr) Composition veterinaire antiprolactinique destinee aux ruminants
ZA201904591B (en) Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs
BR112012018154A2 (pt) agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular
BR112018014791A2 (pt) composições para aprimorar a utilização de nitrogênio em um ruminante
UA117154C2 (uk) Антагоністи s1p3
MX2013013182A (es) Tratamiento de la mastitis.
WO2012009542A3 (en) Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration